| Trial ID: | L0745 |
| Source ID: | NCT03962608
|
| Associated Drug: |
Yaq-001
|
| Title: |
Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis ("NASH-Safety")
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Steatohepatitis
|
| Interventions: |
Device: Yaq-001;Device: Placebo
|
| Outcome Measures: |
Assessment of reported and observed Serious Adverse Events;Assessment of reported and observed Serious Adverse Events;Assessment of reported and observed Serious Adverse Events;Assessment of reported and observed Serious Adverse Events;Assessment of reported and observed Serious Adverse Events;Assessment of reported and observed Serious Adverse Events;Assessment of treatment-related Serious Adverse Events;Assessment of treatment-related Serious Adverse Events;Assessment of treatment-related Serious Adverse Events;Assessment of treatment-related Serious Adverse Events;Assessment of treatment-related Serious Adverse Events;Assessment of treatment-related Serious Adverse Events;Assessment of withdrawals due to Adverse Events;Assessment of withdrawals due to Adverse Events;Assessment of withdrawals due to Adverse Events;Assessment of withdrawals due to Adverse Events;Assessment of withdrawals due to Adverse Events;Assessment of withdrawals due to Adverse EventsDetermine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Determine potential of Yaq-001 for the treatment of NASH;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status;Assessment of changes in nutritional status
|
| Sponsor/Collaborators: |
Yaqrit Ltd
|
| Gender: |
All
|
| Age: |
18 Years70 Years
|
| Phases: |
Not applicable
|
| Enrollment: |
70
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
| Start Date: |
15/05/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 December 2020
|
| Locations: |
France;Italy;Portugal;Spain;Switzerland;United Kingdom;France;Italy;Portugal;Spain;Switzerland;United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT03962608
|
